After 20 years of National Institute of Health funding, the Pharmacogenomics Research Network, PGRN, is now independent scientific society on July 1st, 2020. Thank you for your membership support to establish the new PGRN! The transition is complete, and we have exceeded our membership goals and are off to a great start!
The PGRN Officers and Councilors have a lot planned for the coming months. The mission of the Pharmacogenomics Research Network, henceforth referred to as the “Network” is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects. This will be accomplished by: 1) providing a forum to advance, promote, support, encourage and facilitate communication among researchers, educators and practitioners in pharmacogenomics and related sciences through scientific meetings, seminars, publications and related activities; 2) advancing and promoting research in pharmacogenomics; and 3) providing awareness of the national and international importance of pharmacogenomics.
For PGRN members, please don’t forget to join us on July 17 at 11 AM Eastern Time for the inaugural Research In Progress (RIPS) webinar by Alan Shuldiner, MD. Dr. Shuldiner will speak on "Building bridges between industry, academia, health care systems and communities to advance Precision Medicine". A schedule of upcoming RIPS webinars can be found here. If you are interested in joining the PGRN, you can become a member at www.pgrn.org.